Key Takeaways For California Dentists
-
Adjusted EBITDA, not the headline multiple, usually drives value in a California DSO sale, and every add-back must be documented to survive buyer diligence.
-
California’s corporate-practice-of-dentistry rules require an MSO structure, and the management fee under the MSA reduces buyer-underwritten EBITDA and the valuation.
-
Key value drivers that can raise or lower the multiple include EBITDA margin, doctor dependence, hygiene production, payer mix, and documented systems.
-
Deal structures blend cash at close, rollover equity, and earnouts, and each piece carries different tax treatment, liquidity, and risk that sellers should model before signing.
-
McLerran & Associates produces a diligence-grade, CPA-led valuation and runs a competitive bid process so California owners shape the EBITDA story before a buyer’s quality-of-earnings team does.
Get a diligence-grade valuation before you talk to a buyer.
How DSOs Value A California Dental Practice
A DSO values a dental practice by applying a multiple to its adjusted EBITDA, which means earnings before interest, taxes, depreciation, and amortization, normalized for owner-specific and non-recurring items. The applicable multiple can vary meaningfully based on practice size, profitability, specialty, and market conditions. It reflects documented, transferable earnings rather than a fixed lookup number.
Adjusted EBITDA starts with the practice’s reported operating profit and then applies a series of normalization adjustments. The most significant adjustment is usually owner compensation. Because a DSO must hire a replacement clinician after the sale, the owner’s actual draw is removed and replaced with a market-rate associate salary. The difference between what the owner actually paid themselves and that market replacement cost flows back into EBITDA as an add-back.
Other common add-backs include:
-
Personal expenses run through the practice, such as vehicle leases, club memberships, and above-market family member compensation
-
One-time or non-recurring costs, such as equipment purchases, build-out expenses, and legal settlements
-
Above- or below-market rent paid to a related party
-
Non-recurring consulting or professional fees
Each of those add-backs will be tested. A DSO buyer’s quality-of-earnings team sorts every add-back into three categories: supported by documentation and accepted, probably true but thinly documented and typically haircut, and unsupported and refused. A valuation built on undocumented add-backs rarely survives diligence and often gets re-traded. Practices that hold their valuation are usually the ones that ran the same forensics on themselves first.
Multiples for dental practices in DSO transactions vary by size and structure. Single-doctor and add-on practices have generally clustered in a lower range. Associate-led groups and emerging multi-location platforms tend to command progressively higher multiples as EBITDA grows. The multiple usually reflects documented, transferable, de-owner-dependent earnings rather than a promise.
In California, state law also shapes what a buyer can actually purchase, which changes how that multiple gets applied.
What A DSO Is Actually Buying In California: MSO And Non-Clinical Assets
California enforces one of the most restrictive corporate practice of dentistry frameworks in the country. Under the California Dental Practice Act, a non-dentist entity generally cannot own or control a dental clinical practice. This framework reshapes what a DSO acquires, and therefore what it values, in a California transaction.
The standard solution is a management services organization, or MSO, structure. In this arrangement, the clinical entity, usually a professional corporation, remains owned by a licensed dentist. A separate MSO, controlled by the DSO, owns the non-clinical assets. These include equipment, leasehold improvements, goodwill associated with the business operations, and the management infrastructure. The MSO provides non-clinical administrative services, such as billing, HR, IT, marketing, and procurement, to the professional corporation under a management services agreement, or MSA, and charges a management fee for those services.
That management fee is the single most common place California sellers feel surprised. A DSO buyer models a corporate management fee as a pro forma overhead allocation that reduces the seller’s standalone EBITDA picture. On a practice collecting $2 million annually with $600,000 in reported EBITDA, an 8% management fee of $160,000 lowers buyer-underwritten EBITDA to $440,000. The multiple is then applied to that lower number, which can materially change value.
California’s enforcement environment has also intensified. Recent California Attorney General enforcement actions have scrutinized MSO structures where the management entity exercised control over clinical staffing, compensation, scheduling, or treatment planning. Well-structured MSAs with documented fair-market-value fees and clear separation of clinical governance from administrative services can still work effectively, but the structure should be built carefully.
This article does not provide legal advice. Every California owner should work with their own California healthcare attorney and CPA to evaluate their specific MSO structure. For valuation purposes, the key points are that the management fee is a real economic cost that a buyer will model into underwritten EBITDA, and that the defensibility of the MSA itself is a diligence item in any California DSO transaction.
Key Factors That Move Your Adjusted EBITDA Multiple
The multiple is not arbitrary. The factors below are the ones buyers often weigh most heavily, and each one can raise or lower where your practice lands within the range for its size. You can read them as a checklist. The more of these you can document before going to market, the stronger your negotiating position.
-
EBITDA margin and size. A margin at or above 20% of collections is generally regarded as investment-grade and draws the strongest buyer interest. Larger practices with higher absolute EBITDA attract a broader buyer pool and tend to command higher multiples.
-
Doctor dependence. Associate-led production, where the owner produces less than 70% of chair time, can be the single highest-leverage de-risking variable in dental M&A. Practices where the owner produces the large majority of revenue often face a key-person discount.
-
Hygiene production. Hygiene revenue above 30% of collections can be one of the two highest-leverage value drivers in dental practice valuation. It signals recurring, provider-independent revenue that can continue after the owner’s departure.
-
Payer mix. Fee-for-service-dominant practices tend to trade at the top of published ranges, while Medicaid-heavy practices generally trade at the bottom. Heavy government payer concentration can suppress the multiple and restrict the buyer pool.
-
Documented systems and transferability. Practices with clean financial reporting, interoperable practice management software, and structured clinical protocols are usually easier for a buyer to underwrite and integrate.
-
Operatory capacity and expansion potential. Unused operatory capacity signals growth upside that buyers may capture post-close without additional capital expenditure.
-
Real estate status. Owner-occupied real estate is generally valued separately from the operating practice. A well-structured lease with a reasonable term and renewal options supports a cleaner transaction.
-
Specialty. In general terms, oral and maxillofacial surgery often commands the highest multiples among dental specialties, and general dentistry still earns aggressive valuations in the current market. Specialty premiums usually reflect buyer competition and revenue durability.
-
Multi-location scale. Multi-location regional clusters often command a meaningful platform premium over single-location practices. Once shared management infrastructure is in place, emerging-platform pricing begins to apply.
Cash At Close, Rollover Equity, And Earnouts In California DSO Deals
A DSO offer usually arrives as a package, not a single number. It is typically a blend of three components, and each one carries different tax treatment, liquidity, and risk characteristics.
Cash at close is the most certain component. It is the money received on closing day. Cash at close typically falls in the 60% to 80% of headline enterprise value band for DSO transactions, although the percentage varies by practice size and buyer type.
Rollover equity is ownership in the DSO or its parent platform that the seller retains instead of receiving as cash. Rollover equity can be issued at the practice-entity level, often called joint venture equity, or at the parent holding-company level, and the distinction matters significantly.
-
JV-level equity tracks only the seller’s own locations, is influenced more directly by the seller’s continued performance, and may pay through distributions of practice cash flow. It usually offers a higher floor but a lower ceiling.
-
Holding-company equity tracks every location the platform owns, is influenced by executives the seller rarely meets, and typically pays at a future recapitalization or sale of the whole platform. It usually offers a higher ceiling but no interim distributions and more platform-level risk.
As much as 40% of a DSO deal can be paid in equity rather than cash. In that scenario, the seller is effectively buying stock in the DSO and should evaluate it as an investment. Observed 5-year rollover outcomes range from strong platform exits at 3x to 5x money-on-money to losses at below 1x, with roughly 1 in 5 PE-backed lower-middle-market platforms exiting at or below 1x on the rolled portion.
Earnouts are contingent payments tied to post-sale performance targets, typically EBITDA or collections over 12 to 36 months. The definition of the earnout metric, not just the earnout percentage, usually determines whether any of the money reaches the seller. An earnout measured on EBITDA after the management fee is deducted can produce zero even when clinical performance improves.
On an after-tax basis, the components behave very differently. Goodwill proceeds are generally taxed at long-term capital gains rates: 20% federal plus 3.8% net investment income tax (NIIT) for high earners. Equipment recapture and non-compete payments are taxed as ordinary income at up to 37% federal. California does not conform to the federal preferential capital gains rate, so a California dentist faces up to 13.3% state tax on all gain, for a combined marginal rate approaching 37% on goodwill proceeds.
Rollover equity can defer tax at close under IRC §721 or §351 if properly structured. That deferral comes with illiquidity. Typical holds run 3 to 7 years until the next recapitalization. Over a 3-year horizon, rollover equity may still be locked up with no certainty of value. Over a 5- to 7-year horizon, the outcome depends entirely on the platform’s performance and the sponsor’s ability to execute a successful exit. Always confirm the tax treatment of each deal component with your CPA before signing.
Model your after-tax proceeds across deal structures.
What A DSO Will Ask You For And How To Prepare
DSO buyers request a consistent set of documents so they can rebuild your adjusted EBITDA and test its durability. Before any serious DSO conversation, a California owner should be prepared to provide the documents below. Most of them exist to prove the same point: that your adjusted EBITDA is real, documented, and transferable.
-
Three years of profit and loss statements and tax returns
-
Trailing 12-month collections and production reports by provider
-
Adjusted EBITDA with documented add-backs
-
Owner compensation detail, split between clinical and administrative work
-
Hygiene production as a percentage of total collections
-
Payer mix breakdown, including fee-for-service, PPO, and Medicaid or Denti-Cal
-
Operatory count and current utilization
-
Real estate status, including owned or leased, lease term, and renewal options
-
Associate and hygienist agreements and tenure
-
Post-sale employment intent and transition timeline
A buyer will also run a five-year practice management software audit, not just three years of financials. Institutional buyers run a 36-month EBITDA trajectory and remove non-recurring income from the trailing period without discussion, including pandemic-era credits and one-time insurance settlements. Arriving at any DSO conversation with your own documented EBITDA number, built the same way a buyer would build it, can be one of the most important preparation steps.
A 12–24 Month Pre-Sale Readiness Timeline
Preparation before going to market can protect the multiple. The highest-leverage sale preparation window is 12 to 24 months before market, and the work done in that window can influence whether a practice is classified as a platform or a tuck-in. This timeline counts down to going to market.
A practical timeline looks like this:
-
18–24 months out: Obtain a diligence-grade valuation. Identify add-backs and begin documenting each one with invoices, payroll records, or lease agreements. Review the MSO structure with a California healthcare attorney.
-
12–18 months out: Begin reducing owner dependence. Hire or develop associates, build hygiene recare, and document that production transfers across the provider roster. Clean up personal expenses run through the practice. Confirm commercial PPO in-network status and address any payer mix issues.
-
6–12 months out: Organize three years of clean financials. Confirm lease terms and renewal options. Address any deferred equipment needs that a buyer would model as a post-close capital expenditure. Engage a sell-side advisor and begin the competitive process.
Value drivers such as provider concentration and hygiene performance typically take one to three years of intentional work to shift meaningfully. Waiting until the year of sale to address them usually limits the achievable multiple. The practice that enters the market as a platform rather than a tuck-in often commands a materially different valuation.
Why A Competitive Sale Process Matters In California
A California owner who receives a single unsolicited DSO offer has no way to know whether that offer reflects the market. The offer reflects one buyer’s view of value, and that buyer negotiates deals every week while the owner may sell only once in a career.
McLerran & Associates runs a structured, auction-like bid process. Typical processes run 45 to 60 days, generate around ten offers from a vetted pool of well-qualified buyers, and exclude poorly run DSOs before they ever reach the table. Clients often see around a 30% higher valuation than selling alone. The competitive process can also produce better terms, including more cash at close, more favorable earnout mechanics, and cleaner equity structures.
Frequently Asked Questions
How Does A DSO Value A California Practice Under The MSO Structure?
A DSO values a California dental practice by applying a multiple to adjusted EBITDA, which means the practice’s normalized earnings after replacing owner compensation with a market-rate associate salary and removing non-recurring or owner-specific expenses. Because California’s corporate practice of dentistry law generally prohibits a non-dentist entity from owning the clinical practice, the DSO acquires the non-clinical assets and management infrastructure through an MSO, while the professional corporation remains dentist-owned. The management fee the MSO charges under the management services agreement is modeled as a post-close overhead cost that reduces the buyer’s underwritten EBITDA. The multiple is then applied to that lower, buyer-adjusted figure, so understanding the management fee’s interaction with EBITDA can be essential before evaluating any California DSO offer.
Does The 50-40-30 Rule Still Apply To DSO Valuations?
The 50-40-30 rule is an overhead benchmark for dental practices. It suggests overhead should be no more than 50% of collections for a solo practice, 40% for a small group, and 30% for a mature DSO platform. It remains a useful reference for operational health, but it is not how DSO buyers underwrite a practice. Institutional buyers normalize EBITDA using their own overhead benchmarks, which are generally tighter than ADA averages, and then apply a management fee allocation on top. A practice that looks healthy by the 50-40-30 standard may still produce a lower buyer-underwritten EBITDA than the owner expects once the management fee and compensation normalization are applied. For a DSO sale, the central question is whether the adjusted EBITDA is documented, defensible, and transferable.
How Does California’s Corporate Practice Of Dentistry Law Affect Valuation?
California’s corporate practice of dentistry doctrine means a DSO generally cannot acquire the clinical entity outright. Instead, the transaction is structured so the MSO acquires non-clinical assets and provides management services, while the professional corporation remains dentist-owned. This has two direct valuation consequences:
-
The management fee charged under the MSA is a real economic cost that reduces buyer-underwritten EBITDA and therefore the enterprise value the multiple is applied to.
-
The MSA itself is a diligence item. A well-documented MSA with fair-market-value fees and clear clinical governance separation supports a cleaner transaction, while a poorly structured one can create regulatory and valuation risk.
Every California owner should review their MSO structure with a California healthcare attorney before going to market.
How Do Cash Versus Rollover Equity Change The Real Outcome?
Cash at close is the only component of a DSO deal that arrives on closing day without timing or performance risk. Rollover equity is a claim on the platform’s future value. It is typically illiquid for three to seven years, sits behind the sponsor’s preferred capital, and can be worth anywhere from a multiple of its face value to zero depending on the platform’s performance and exit timing. On an after-tax basis in California, goodwill proceeds are taxed at federal long-term capital gains rates plus California’s ordinary income rate of up to 13.3%, which creates a combined marginal rate approaching 37% on goodwill. Rollover equity can defer tax at close if properly structured, but that deferral is only valuable if the equity ultimately pays out. A seller who takes 30% of their deal in rollover equity and then experiences platform underperformance may net less after tax over a seven-year horizon than a seller who negotiated a higher cash-at-close percentage at a slightly lower headline number. McLerran & Associates models these outcomes across 3-, 5-, and 7-year horizons so clients can compare real after-tax proceeds across deal structures before choosing a path.
Conclusion: Shape Your EBITDA Story Before Buyers Do
A DSO valuation reflects documented, transferable, de-owner-dependent adjusted EBITDA that sits within California’s MSO structure. That EBITDA is tested by a buyer’s quality-of-earnings team and multiplied by a range that reflects the practice’s size, profitability, and transferability. The California owner who arrives at that conversation with a diligence-grade EBITDA analysis usually controls the narrative. The owner who arrives relying on a buyer’s free valuation often negotiates from the buyer’s starting point.
McLerran & Associates is a dental-only, sell-side advisor that produces a diligence-grade, CPA-led valuation and runs a competitive process among a vetted pool of well-qualified buyers. The goal is a number that holds when buyers scrutinize it and a deal that does not get re-traded. With roughly 2,000 successful practice sales, more than $2 billion in closed transaction volume, and a team carrying over 100 years of collective dental-industry experience, McLerran focuses on helping dentists sell practices, not just list them.
Control the EBITDA narrative with a confidential call.
Not sure if selling is right for you yet? Ask about the McLerran M&A Summit, October 29–30, 2026.
